PIN9 Effectiveness Of The Monovalent Rotavirus Vaccine In Colombia Through Different Analyses Within An Ecological Study  by Paternina-Caicedo, A. et al.
A80 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
(HR=4.46, p<0.001), and sepsis-related infections (HR=2.76, p<0.001) while 
controlling for other patient characteristics. CONCLUSIONS: This study provides 
evidence that VHA patients with MS are more likely than non-MS patients to be 
hospitalized due to infection. Efforts to reduce these complications may improve 
patient health while lowering health care costs.  
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OBJECTIVES: To assess the clinical characteristics, utilization, and cost patterns 
of human immunodeficiency virus (HIV) patients in the U.S. veteran population. 
METHODS: A retrospective analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with HIV were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis codes 042.xx and V08.xx. Descriptive statistics were calculated as 
means ± standard deviation (SD) and percentages to measure comorbidities, 
cost, and utilization distribution in the sample. Health care resource utilization 
and costs were assessed for the 12-month follow-up period. Clinical status and 
laboratory tests were examined for the 12-month baseline period before disease 
identification. RESULTS: A total of 10,873 patients were diagnosed with HIV from 
2006 to 2011 in the U.S. veteran population. Common comorbidities included 
hypertension (n=1,047, 9.63%), depressive disorder (n=590, 5.43%) and diabetes 
mellitus (n=499, 4.59%). Outpatient services were utilized by 99.77% of  
HIV patients, followed by pharmacy visits (89.70%) and inpatient visits (27.67%). 
Costs for outpatient ($13,338, SD=$15,709), pharmacy ($5,345, SD=$8,593) and 
inpatient services ($12,072, SD=$45,507) contributed to follow-up health care 
expenditures. The top three treatments for U.S. veteran HIV patients  
were sulfamethoxazole/trimethoprim, efavirenz/emtricitabine/tenofovir, and 
emtricitabine/tenofovir. Among 10,873 HIV patients, a total of 1,295 (11.91%) had 
CD-4 tests, of which 142 patients had values ≤50. A total of 847 patients (7.79%) 
had the HIV viral load test, of which 194 patients had values >100,000. 
CONCLUSIONS: Sulfamethoxazole/trimethoprim, efavirenz/emtricitabine/ 
tenofovir, and emtricitabine/tenofovir were the most frequently prescribed  
HIV medications. More research is required to better understand the  
economic benefits and adverse events of effective antiretroviral medications and 
regimens.  
 
PIN6  
EPIDEMIOLOGY AND COSTS OF MENINGOCOCCAL DISEASE IN BRAZIL:  
A SURVEY OF THE LITERATURE  
Carpiuc KT1, Snedecor SJ1, Roberts CS2, Fujii RK3 
1Pharmerit International, Bethesda, MD, USA, 2Pfizer, New York, NY, USA, 3Pfizer, Inc.,  
São Paulo, Brazil  
OBJECTIVES: To review the epidemiology and economic burden of 
meningococcal disease (MD) in Brazil. METHODS: A literature review was 
conducted to identify epidemiologic and economic data on MD and subsequent 
sequelae. Terms “meningitis,” “meningococcal vaccines,” “meningococcal 
disease,” “Neisseria meningitidis,” and “Brazil” with “cost OR econ*” were used to 
search Medline. Supplemental data from internet searches, article references, 
and other Latin American countries were also reviewed. RESULTS: In 2009, Brazil 
had 19,708 confirmed cases of meningitis, of which 6,981 (35.4%) were bacterial. 
Of these, 2,603 (37.3%) were MD. There has been a downward trend in the 
incidence of MD over the last 15 years, which has stabilized to <2 cases/100,000 
population in recent years. The incidence is highest in children <5 years, ranging 
from 10.1 cases/100,000 in infants <1 year to 4.1 cases/100,000 in children 1-4 
years. The case fatality rate for MD is high compared to others worldwide (~20% 
vs.10%). The cost burden of bacterial meningitis and disease sequelae has been 
estimated to comprise direct costs of medical visits, hospital admissions, 
laboratory tests, imaging studies, medications, and transportation to health 
services, as well as costs of work loss from the caregiver. Few studies reported 
direct costs of an MD episode, which ranged from (R$1,000-1,500) in children <9 
years. Corresponding data of costs for MD in adults were not found. Costs of 
sequelae were estimated to be highest for neurological impairment (R$8,053 and 
R$19,154 with indirect costs; 2006 BRL). Data on carriage prevalence rates of N 
meningitidis, the causative agent of MD, were unavailable from Brazil. 
CONCLUSIONS: With active surveillance in Brazil where MD is endemic, 
epidemiology data is robust, but detailed information on the economic burden is 
limited. Carriage rates of N meningitidis are poorly documented in Brazil, which is 
a barrier to understanding disease transmission and potential prevention 
strategies.  
 
PIN7  
A SYSTEMATIC REVIEW OF DIAGNOSTIC ACCURACY OF FDG PET/PET-CT FOR 
FEVER OF UNKNOWN ORIGIN  
Lee DH1, Park DA1, Lee NR1, Kwak S1, Lee YK1, Park S2, Park Y3, Paeng J4 
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Division 
of Infectious Diseases, Seoul National University Hospital, Seoul, South Korea, 3Department of 
Internal Medicine, Gachon University Gil Hospital, Incheon, South Korea, 4Department of Nuclear 
Medicine, Seoul National University Hospital, Seoul, South Korea  
OBJECTIVES: Fever of unknown origin (FUO) is defined as temperature > 101°F on 
several occasions duration of fever of more than 3 weeks and failure to reach to 
diagnosis despite one week of inpatient investigations. This study aimed to 
perform a systematic review to examine the overall diagnostic performance of 
FDG-PET/PET CT in identifying the causal source of FUO. METHODS: We 
searched potentially relevant studies using electronic databases such as Ovid-
Medline, Ovid-EMBASE, Cochrane library, KoreaMed, and Kmbase from their 
inception to May, 2012. Two independent reviewers extracted data using a 
standardized form. The quality of the selected studies was assessed using 
QUADAS-2. A bivariate random model was constructed to summarize the 
sensitivity, specificity and area under the curve (AUC). RESULTS: A total of 15 
studies representing 592 patients were eligible for inclusion. Overall, the studies 
had ‘poor’ methodological quality. Concerns about applicability are rated as 
‘low’. AUC of 6 FDG-PET studies was 0.7955, and the pooled diagnostic odds ratio 
(DOR) was 9.38 (95% CI 1.44-60.91). Pooled sensitivity was 0.859 (95% CI 0.729-
0.932), and the pooled specificity was 0.664 (95% CI 0.416-0.845). As the results of 
meta-regression in accordance with the absence of blinding that causes 
heterogeneity, pooled specificity was significant difference (blinding 0.816, non-
blinding/unclear 0.344, P=0.013). AUC of 9 FDG PET-CT studies was 0.8071, and 
the pooled DOR was 10.93 (95% CI 4.67-25.57). Pooled sensitivity was 0.838 (95% CI 
0.715-0.914), and the pooled specificity was 0.714(95% CI 0.588-0.814). 
CONCLUSIONS: FDG PET/PET-CT test appeared to have a high sensitivity and a 
moderate specificity for the detection of the causes of FUO. However, since a 
limited number of studies are available and included studies were 
heterogeneous with respect to the aspect of study design, the method of 
interpretation of test result. More rigorous and larger prospective studies are 
needed.  
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OBJECTIVES: Two NS3/4A protease inhibitors (PIs), telaprevir and boceprevir, 
were recently approved in the United States. Even though several randomized 
controlled trials (RCTs) have demonstrated the efficacy and safety of PIs, a meta-
analysis using various subgroup analyses based on patient characteristics has 
not been conducted. The objectives were to compare the efficacy and safety of 
these PIs in patients with chronic hepatitis C genotype 1, based on PI type and 
patient characteristics. METHODS: Both published and unpublished RCTs were 
selected if they: 1) compared triple therapies (telaprevir or boceprevir + peg-
interferon + ribavirin) and dual therapy (peg-interferon + ribavirin); 2) had 
treatment groups that met FDA-approved dosages; and 3) measured the outcome 
using sustained virologic response (SVR). RESULTS: A total of 4421 patients from 
10 evaluated articles were included in the meta-analysis. Overall, triple therapy 
was significantly associated with a higher achievement of SVR than dual therapy 
(odds ratio [OR] = 3.959; 95% confidence interval [CI], 3.146 to 4.981). When 
administering triple therapy, the likelihood of achieving SVR in telaprevir-
treated patients (OR = 4.292; 95% CI, 2.893 to 6.369) was significantly different 
than that in boceprevir-treated patients (OR = 3.634; 95% CI, 2.777 to 4.754). The 
likelihood of achieving SVR with triple therapy compared to dual therapy was 
statistically significantly higher in treatment-experienced patients (OR = 7.544; 
95% CI, 5.919 to 9.615) compared to treatment-naïve patients (OR = 3.026; 95% CI, 
2.641 to 3.466). Patients on triple therapies had an increased incidence of 
treatment discontinuation attributable to adverse events when compared with 
the dual therapy, regardless of PI type and patients’ treatment experience. 
CONCLUSIONS: Regarding achieving SVR, triple therapies including either PI are 
superior to dual therapy for both previously untreated and previously treated 
patients.  
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OBJECTIVES: Monovalent rotavirus vaccine (MNV) was introduced in 2009 in 
Colombia. Despite ecological studies are a major tool in epidemiology, bias may 
influence them. The aim of this study is to assess the effectiveness of the MNV 
in Colombia through several analyses within an ecological study. METHODS: 
Data was collected from the Colombian national statistical agency (DANE) from 
1999-2010 for diarrhea deaths and population under-1 year old. This study made 
the following analyses: 1) Incidence rate ratios (IRR) for regions (states), with 
MNV coverage <50% as reference (low vaccination coverage) and >75% as high 
vaccination coverage; 2) Negative binomial regression pre and post vaccination 
in low and high coverage states; and 3) a longitudinal panel data analysis by 
states of Colombia. RESULTS: 1) As the vaccination coverage increased, the 
reduction of diarrhea-related infant mortality was greater (R-square=0.41). Death 
rate was lower in states with higher coverage in the post vaccination period 
(77.25 deaths per 100,000 people versus 18.31 deaths per 100,000 people); 2) 
Prevaccination trend (1999-2008) of diarrhea-related mortality was between -5.7% 
(95%CI, -0.87% -10.36%) for low coverage states to -9.43% (95%CI, -6.7 – -12.08) for 
high coverage states, and postvaccination trends (2009-2010) were -8.83% (95%CI, 
33.94 to -37.94) for low coverage states and -37.46% (95%CI, -15.34 – -53.8) for high 
coverage states; 3) Multivariable panel regression showed that for each percent 
point the MNV coverage increased, the diarrhea-related mortality decreased by -
0.9% (95%CI, -0.6% – -1.1%). CONCLUSIONS: The post vaccination decrease of 
diarrhea-related infant mortality was robust to changes in analysis. Even further, 
our results strongly suggest better vaccine coverage may be needed for a greater 
MNV vaccine effectiveness.  
